| Name | Title | Contact Details |
|---|
Princeton BioMeditech Corporation is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The healthcare industry is at a critical juncture, where every effort is being made to increase the effectiveness of care, while decreasing the financial burden on our system. With the introduction of BioTelemetry, we aim to lead in the advancement of mobile health monitoring by providing unmatched products and services to help healthcare professionals track and diagnose patients in a more efficient, accurate, and cost-effective manner. In April 2013, our predecessor company, CardioNet, Inc. (NASDAQ: BEAT), announced plans to adopt a holding company structure to more effectively facilitate our ongoing growth plans. With this change, our strategy is to achieve sustained long-term growth by solidifying our leadership position in remote cardiac monitoring, building a leading research services business, and identifying markets that would benefit from the application of our wireless platform and proprietary technology. We currently have four subsidiaries: CardioNet & Mednet- cardiac medical device & monitoring services, Braemar- cardiac manufacturing, Cardiocore- cardiac clinical research. Please visit our subsidiary pages for more information.
Natera Inc. is a genetic testing company that specializes in analyzing tiny quantities of DNA for reproductive health. Natera operates a CLIA-certified laboratory in San Carlos, Calif., providing a host of preconception and prenatal genetic testing services. Test offerings include pre-implantation genetic diagnosis to identify chromosomal anomalies or inherited genetic conditions in embryos generated during an IVF cycle; products-of-conception testing following miscarriage to analyze fetal chromosomes and understand the cause of the pregnancy loss; non-invasive prenatal testing to determine paternity; carrier screening to detect whether parents carry genetic variations that may result in disease in the child; and Panorama, a safe, simple test for pregnant women that identifies the most common chromosomal anomalies in a fetus as early as nine weeks of gestation. Natera's PreNATUS clinical trial for non-invasive screening of fetal chromosomal anomalies is funded by the NIH and is being conducted by the leaders in maternal-fetal medicine in the United States. These tests were developed by Natera, a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). They have not been cleared or approved by the U.S. Food and Drug Administration (FDA). In August, Natera was selected by the World Economic Forum as a Technology Pioneer for innovations in prenatal care. For more information, visit www.natera.com.